These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 26437033)
21. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969 [TBL] [Abstract][Full Text] [Related]
23. Periductal Stromal Tumor of the Breast with a Anderson B; Marotti JD; Lefferts JA; Muller KE Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780 [TBL] [Abstract][Full Text] [Related]
24. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations. Otsuji K; Sasaki T; Tanabe M; Seto Y Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803 [TBL] [Abstract][Full Text] [Related]
25. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Tan WJ; Cima I; Choudhury Y; Wei X; Lim JC; Thike AA; Tan MH; Tan PH Breast Cancer Res; 2016 Mar; 18(1):31. PubMed ID: 26961242 [TBL] [Abstract][Full Text] [Related]
26. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993 [TBL] [Abstract][Full Text] [Related]
27. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women. Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586 [TBL] [Abstract][Full Text] [Related]
28. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast. Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988 [TBL] [Abstract][Full Text] [Related]
29. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Wang ZC; Buraimoh A; Iglehart JD; Richardson AL Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486 [TBL] [Abstract][Full Text] [Related]
30. Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study. Tan BY; Md Nasir ND; Chang HY; Ng CCY; Guan P; Nagarajan S; Rajasegaran V; Lee JY; Lim JQ; Thike AA; Teh BT; Tan PH Mod Pathol; 2020 Sep; 33(9):1732-1745. PubMed ID: 32322022 [TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162 [TBL] [Abstract][Full Text] [Related]
32. A Diagnostic Approach to Fibroepithelial Breast Lesions. Tan BY; Tan PH Surg Pathol Clin; 2018 Mar; 11(1):17-42. PubMed ID: 29413655 [TBL] [Abstract][Full Text] [Related]
33. Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast. Kang Y; Kim JH; Lee TH; Kim TS; Jung WH; Chung HC; Park BW; Sheen SS; Han JH Hum Pathol; 2009 Jan; 40(1):98-107. PubMed ID: 18789487 [TBL] [Abstract][Full Text] [Related]
34. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Huang KT; Dobrovic A; Yan M; Karim RZ; Lee CS; Lakhani SR; Fox SB Breast Cancer Res Treat; 2010 Nov; 124(2):555-65. PubMed ID: 20563638 [TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Feakins RM; Wells CA; Young KA; Sheaff MT Hum Pathol; 2000 Oct; 31(10):1214-22. PubMed ID: 11070114 [TBL] [Abstract][Full Text] [Related]
37. Phyllodes tumors and fibroadenoma common beginning and different ending. Oprić S; Oprić D; Gugić D; Granić M Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226 [TBL] [Abstract][Full Text] [Related]
38. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752 [TBL] [Abstract][Full Text] [Related]
39. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Lawton TJ; Acs G; Argani P; Farshid G; Gilcrease M; Goldstein N; Koerner F; Rowe JJ; Sanders M; Shah SS; Reynolds C Int J Surg Pathol; 2014 Dec; 22(8):695-8. PubMed ID: 25161205 [TBL] [Abstract][Full Text] [Related]
40. Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Djordjevic B; Hanna WM Mod Pathol; 2008 Oct; 21(10):1238-45. PubMed ID: 18500266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]